Not available
Quote | Aeterna Zentaris Inc. (NASDAQ:AEZS)
Last: | $2.46 |
---|---|
Change Percent: | 4.0% |
Open: | $2.4 |
Close: | $2.46 |
High: | $2.5115 |
Low: | $2.3 |
Volume: | 25,010 |
Last Trade Date Time: | 10/02/2023 03:00:00 am |
News | Aeterna Zentaris Inc. (NASDAQ:AEZS)
TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products,...
2023-08-09 14:48:51 ET Aeterna Zentaris press release ( NASDAQ: AEZS ): Q2 GAAP EPS of -$0.52. Revenue of $2.2M. Total revenue for the three-month period ended June 30, 2023 was $2.2 million as compared with ($0.2 million) for the same period in 2022, representing an i...
Message Board Posts | Aeterna Zentaris Inc. (NASDAQ:AEZS)
Subject | By | Source | When |
---|---|---|---|
were they trying to eliminate COVID -9.or what | ernie44 | investorshub | 04/09/2023 4:25:56 PM |
exactly,i have no idea what we were thinking,live | livendi | investorshub | 04/09/2023 3:17:43 AM |
Nearly all management had been in this company | Patrickwan1 | investorshub | 04/08/2023 9:10:31 PM |
This company has been listed for more than | Patrickwan1 | investorshub | 04/08/2023 8:07:06 PM |
me too bro,God bless and good luck | livendi | investorshub | 04/04/2023 7:13:18 PM |
Aeterna Zentaris Inc. Company Name:
AEZS Stock Symbol:
NASDAQ Market:
TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products,...
Ended the quarter with $42.2 million in cash, expected to fund operations into 2025 Driving patient recruitment for Phase 3 DETECT trial for the diagnosis of Childhood Onset Growth Hormone Deficiency TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) ...
Highlights progress, recent developments and upcoming key milestones C ompany c ontinu es to build growing body of data across pipeline , a dvancing towards first in human studies S trong financial position with cash projected to fund op...